App-Quantinova.ai

The relationship between Flutriciclamide PET uptake and grey matter atrophy in mild cognitive impairment and Alzheimer’s disease

Sanara Raza - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Mild cognitive impairment

N/A

Assessments of instrumental activities of daily living in low-middle income countries: a systematic review (word count: 350/350).

Ríona Mc Ardle - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Cultural adaptation and validation of the Addenbrooke’s Cognitive Examination III in a Taiwanese population (T-ACE-III) presenting to hospital with suspected dementia

Ruan-Ching Yu - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dementia

N/A

The effect of illiteracy on performance in screening tools for dementia: a systematic review and meta-analysis

Caragh Maher - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dementia

N/A

Development and External Validation of a Novel Dementia Risk Prediction Score in the UK Biobank Cohort

Melis Anatürk - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dementia

N/A

Engagement with a preventive eHealth intervention in older adults (the HATICE trial): predictive factors and associations with dementia and cardiovascular risk

Nicola Coley - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Dementia

N/A

Lifestyle and behavior changes during the COVID19 pandemic in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER)

Jenni Lehtisalo - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dementia

N/A

Multimodal Preventive Trial for Alzheimer’s Disease (MIND-ADMINI): Pilot trial progress and results

Miia Kivipelto - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

Neural correlates of cognitive resilience differ between experiences of bilingualism and education: A cortical surface-based morphometry study in dementia

Suvarna Alladi - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Frontotemporal dementia

N/A

Occupational complexity and neuroimaging measures of structural MRI and PET-amyloid in a randomized controlled trial: FINGER

Anders Rydström - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

Participants experiences form a multi modal dementia prevention trial: MIND-AD

Ulrika Akenine - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dementia

N/A

PHYSICAL ACTIVITY AND SEDENTARY TIME IN A MULTIMODAL LIFESTYLE INTERVENTION IN PRODROMAL ALZHEIMER’S DISEASE: THE MIND-ADMINI PILOT TRIAL

Charlotta Thunborg - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

The effects of age and hypertension on cerebral small vessel disease differ between men and women at midlife: the PREVENT-Dementia study

Audrey Low - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Cerebral small vessel disease

N/A

The WW-FINGERS-SARS-CoV2 initiative: Impact of the COVID-19 Pandemic on Brain Health and Prevention Strategies

Francesca Mangialasche - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hypertension

N/A

WW-FINGERS-SARS-CoV2 in Finland: Changes in Lifestyle and Risk Factors for Cognitive Impairment During the Pandemic in the FINGER Study

Tiia Ngandu - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Phosphorylation of the M1 muscarinic acetylcholine receptor protects from neurodegeneration

Miriam Scarpa - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Acetylcholine

Immune protein levels in cerebrospinal fluid: associations with memory scores across the AD spectrum

Kirsten E. J. Wesenhagen - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dementia

N/A

TNF-mediated activation of necroptosis signaling in AD hippocampus

Anusha Jayaraman - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

TL32711

Cognitive decline in possible Vascular Cognitive Impairment (VCI); does the form of vascular brain injury matter?

Jooske Boomsma - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

White matter hyperintensities

N/A

Higher levels of the astrocytic marker CSF YKL40 are associated to better memory performance only in amyloid positive individuals with subjective cognitive decline

Gonzalo Sánchez-Benavides - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Filters

45280 Abstracts